SCHEMBL303124

SCHEMBL303124

c1ccc2c(P(C3CCCCC3)C3CCCCC3)cccc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
EPHX1 P07099 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACP3 P15309 1/20 0.36
HSD17B10 Q99714 2/20 0.36
MAPT P10636 1/20 0.36
MPI P34949 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15659500 0.90 ALDH1A1 (0.39) ALDH1A1MEN1RAB9AKMT2AHSD17B10
SCHEMBL5608644 0.86 HTR7 (0.37) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL15659124 0.85 ALDH1A1 (0.39) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL15658703 0.82 ALDH1A1 (0.37) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL160594 0.82 ALDH1A1 (0.37) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL30391805 0.82 ALDH1A1 (0.37) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL1315359 0.82 ROCK2 (0.35) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL15656937 0.81 ALDH1A1 (0.36) ALDH1A1EPHX1KDM4EMEN1RAB9A
SCHEMBL164194 0.80 ALDH1A1 (0.38) ALDH1A1EPHX1HSD17B10MAPTMPI
SCHEMBL31566355 0.80 ALDH1A1 (0.38) ALDH1A1EPHX1HSD17B10MAPTMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2735581-B1 COMPOSITION AND POLYMER ASAHI CHEMICAL IND (JP) 2021-07-14 EP disclosed
WO-2019161649-A1 1-(8-ARYLNAPHTHYL)PHOSPHINE LIGAND AND PREPARATION METHOD THEREFOR, AND PHOSPHINE GOLD COMPLEX AND USE 华中师范大学 2019-08-29 WO disclosed
US-9738757-B2 Composition and polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2017-08-22 US disclosed
CN-103502315-B Composition and polymer 旭化成株式会社 2016-08-17 CN disclosed
US-20160222168-A1 Composition and Polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-08-04 US disclosed
CN-105754099-A Composition and polymer 旭化成株式会社 2016-07-13 CN disclosed
US-9334371-B2 Composition and polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-05-10 US disclosed
EP-2735581-A1 COMPOSITION AND POLYMER Asahi Kasei Chemicals Corporation (JP) 2014-05-28 EP disclosed
US-20140121293-A1 Composition and Polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2014-05-01 US disclosed
CN-103502315-A Composition and polymer ASAHI KASEI CHEMICALS CORP 2014-01-08 CN disclosed
US-7560582-B2 Ligands for metals and improved metal-catalyzed processes based thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-07-14 US disclosed
EP-2076512-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-07-08 EP disclosed
US-20080200729-A1 Preparation of Aryl Phosphines RHODIA UK LIMITED (GB) 2008-08-21 US disclosed
US-20080200729-A1 Preparation of Aryl Phosphines RHODIA UK LIMITED (GB) 2008-08-21 US disclosed
US-20080200729-A1 Preparation of Aryl Phosphines RHODIA UK LIMITED (GB) 2008-08-21 US disclosed
WO-2008044022-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-17 WO disclosed
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-02-07 US disclosed
US-7223879-B2 Ligands for metals and improved metal-catalyzed processes based thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-05-29 US disclosed
EP-1673378-A1 PREPARATION OF ARYL PHOSPHINES Rhodia UK Limited (GB) 2006-06-28 EP disclosed
WO-2005023823-A1 PREPARATION OF ARYL PHOSPHINES RHODIA UK LIMITED (GB) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200729-A1 Preparation of Aryl Phosphines PRXL2A, PRDX1, TPO ALDH1A1 3530/4885EPHX1 321/4885KDM4E 3721/4885
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon THEM6, SOD1, SLC30A6 ALDH1A1 2074/4885EPHX1 3052/4885KDM4E 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.